CHARACTERIZATION OF PHARMACOKINETICS OF 2-((3-(CHLOROMETHYL)BENZOYL)OXY) BENZOIC ACID IN RATS BY USING HPLC-DAD METHOD
Objective: A new compound of salicylic acid derivative, namely 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3CBB), was synthesized to find a compound exhibiting higher analgesic activity and smaller ulcer irritation than acetylsalicylic acid (ASA). Therefore, this study aimed to investigate the pharmacokinetics of this new compound in rats, following a single dose oral administration of 3CBB (45 mg/kg BW).
Methods: Plasma samples of 9 healthy rats were collected before and up to 3 h after its oral administration, following an 18 h fasting period. Plasma concentrations of 3CBB were determined using a validated HPLC-DAD assay. Pharmacokinetic parameters were determined using the compartment model technique. All experiments were carried out in triplicate.
Results: The pharmacokinetic parameters of 3CBB obtained were as follows: Tmax= 28.9±1.1 min, Cmax = 0.57±0.02 µg/ml, AUCtotal = 66.3±1.0 µg min/ml, Kel = 0.018±0.002 min-1, and T1/2el = 39.4±3.9 min. The long elimination half-life and low Cmax indicated that 3CBB was extensively distributed in the deep and very deep tissues. This confirmed the unique and special characteristics of a highly lipophilic compound like 3CBB (log P = 3.73).
Conclusion: 3CBB demonstrated a slower onset of action and longer elimination time from the body compared to ASA. Thus this new compound is a potential candidate to be developed as a new drug.
2. Levy G. Clinical pharmacokinetics of aspirin. Pediatrics 1978;62(5 Suppl 2):867-72.
3. Fu CJ, Melethil S, Mason WD. The pharmacokinetics of aspirin in rats and the effect of buffer. J Pharmacokinet Biopharm 1991;19:157–73.
4. Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T. Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol 2014;6:51-9.
5. Byod EM. The acute oral toxicity of acetylsalicylic acid. Toxicol Appl Pharmacol 1959;1:229-39.
6. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219-26.
7. Caroline, Foe K, Esar SY, Retnowati E, Soewandi A, Wihadmadyatami H, et al. Evaluation of analgesic and antiplatelet activity of 2-((3-(Chloromethyl)benzoyl)oxy) benzoic acid. prostaglandins and other lipid mediator. Prostaglandins Other Lipid Mediator 2019;145:106364.
8. Saeed AM, Hamzah MJ, Ahmed NQ. Quantitative assay of aspirin and (Salicylic Acid and Heavy Metals as Impurities) in Iraqi’s market aspirin tablets using different analytical methods. Int J Appl Pharm 2018;10:167-72.
9. Pisal P, Nigade G, Kale A, Pawar S. Development and validation of stability indicating RP-HPLC method for simultaneous determination of aspirin, rosuvastatin, clopidogrel in bulk and pharmaceutical dosage form. Int J Pharm Pharm Sci 2018;10:51-6.
10. U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM), Bioanalytical Method Validation; 2018.
11. Ramesh D, Habibuddin M. Development and validation of RP-HPLC method for the determination of alvimopan in rat plasma. Int J Pharm Pharm Sci 2018;10:124-9.
12. Togami K, Fukuda K, Yamaguchi K, Chono S, Tada H. Facile and sensitive HPLC-UV method for determination of nintedanib in rat plasma. Int J Pharm Pharm Sci 2018;10:133-7.
13. Melo A, Almeida HL, Ferreira C, Sousa N, Pego JM. Exposure to ketamine anesthesia affects rat impulsive behavior. Front Behav Neurosci 2016;10:226.
14. Wientjes MG, Levy G. Nonlinear pharmacokinetics of aspirin in rats. J Pharmacol Exp Ther 1988;245:809-15.
This work is licensed under a Creative Commons Attribution 4.0 International License.